Buy Revolade : Eltrombopag 50 mg Tablets Online

Description

1. Composition:

• Eltrombopag: Revolade contains eltrombopag as its active pharmaceutical ingredient. Eltrombopag is a thrombopoietin receptor agonist used in the treatment of certain disorders related to low platelet counts. It works by stimulating the production of platelets in the bone marrow, thereby increasing platelet counts in the blood.

2. Indications:

• Thrombocytopenia: Revolade is indicated for the treatment of thrombocytopenia (low platelet count) in patients with chronic immune thrombocytopenia (ITP), severe aplastic anemia (SAA), or chronic hepatitis C virus (HCV) infection.
• Hepatitis C-Associated Thrombocytopenia: In patients with chronic HCV infection, Revolade is used to increase platelet counts in order to allow the initiation and maintenance of interferon-based therapy.

3. Dosage and Administration:

• The recommended starting dosage of Revolade for most patients with chronic immune thrombocytopenia (ITP) is 50 mg once daily.
• The dosage may be adjusted based on platelet counts and clinical response, with a maximum recommended dosage of 75 mg once daily.
• Revolade should be taken orally, with or without food, and swallowed whole with a glass of water.
• It is important to follow the dosage instructions provided by a healthcare professional.

4. Effectiveness:

• Revolade has been shown to effectively increase platelet counts in patients with chronic immune thrombocytopenia (ITP), severe aplastic anemia (SAA), and chronic hepatitis C virus (HCV) infection.
• By stimulating platelet production in the bone marrow, Revolade helps reduce the risk of bleeding episodes and allows for the initiation and maintenance of necessary medical treatments.

5. Safety Profile:

• Revolade is generally well-tolerated when used as prescribed. Common side effects may include headache, nausea, diarrhea, fatigue, and muscle pain.
• Serious side effects such as hepatotoxicity, thromboembolism, and bone marrow reticulin formation are rare but possible.
• Patients should be monitored regularly for signs of adverse reactions, including liver function tests and blood cell counts.

6. Contraindications:

• Revolade is contraindicated in patients with a hypersensitivity to eltrombopag or any of the excipients in the formulation.
• It should not be used in patients with thrombocytopenia due to myelodysplastic syndrome (MDS) or in patients with a history of thromboembolism.

7. Precautions:

• Revolade should be used with caution in patients with hepatic impairment, as it may exacerbate pre-existing liver conditions.
• It should be avoided in pregnant or breastfeeding women unless the potential benefits outweigh the risks.

8. Storage:

• Revolade should be stored at room temperature (25°C) in a dry place, away from moisture and heat.
• Keep the medication out of reach of children and pets.

Revolade tablets, containing eltrombopag as the active ingredient, represent a valuable treatment option for patients with thrombocytopenia associated with various medical conditions. Treatment should be initiated and monitored by a qualified healthcare professional, and patients should be informed about potential side effects and precautions associated with the use of Revolade.